Breast radiotherapy for ductal carcinoma in situ: could less be more?
- PMID: 35933995
- DOI: 10.1016/S0140-6736(22)01381-2
Breast radiotherapy for ductal carcinoma in situ: could less be more?
Comment on
-
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.Lancet. 2022 Aug 6;400(10350):431-440. doi: 10.1016/S0140-6736(22)01246-6. Lancet. 2022. PMID: 35934006 Clinical Trial.
Similar articles
-
Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost?Lancet. 2023 Jan 7;401(10370):23-24. doi: 10.1016/S0140-6736(22)02399-6. Lancet. 2023. PMID: 36610767 No abstract available.
-
Adjuvant Radiation Therapy for Ductal Carcinoma In Situ of the Breast: A Clinician's Dilemma.Ann Surg Oncol. 2023 Oct;30(11):6281-6283. doi: 10.1245/s10434-023-13691-1. Epub 2023 Jun 6. Ann Surg Oncol. 2023. PMID: 37280311 No abstract available.
-
Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast.CA Cancer J Clin. 1997 Jan-Feb;47(1):52-64. doi: 10.3322/canjclin.47.1.52. CA Cancer J Clin. 1997. PMID: 8996078 Review.
-
Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? - Authors' reply.Lancet. 2023 Jan 7;401(10370):24. doi: 10.1016/S0140-6736(22)02373-X. Lancet. 2023. PMID: 36610769 No abstract available.
-
Part V. Adjuvant therapies for ductal carcinoma in situ.Curr Probl Cancer. 2000 May-Jun;24(3):163-74. doi: 10.1016/s0147-0272(00)90016-3. Curr Probl Cancer. 2000. PMID: 10919317 Review. No abstract available.
Cited by
-
[Boost and hypofractionation in DCIS].Strahlenther Onkol. 2022 Dec;198(12):1122-1124. doi: 10.1007/s00066-022-02016-y. Epub 2022 Oct 20. Strahlenther Onkol. 2022. PMID: 36264356 Free PMC article. German. No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical